Sleiman, J., Charabaty, A., & Rahman, A. ur. (2021). Do pharmacokinetics justify dose-optimization for loss of response to Vedolizumab in IBD?. @Gijournal, 1(1). https://doi.org/10.52697/gijournal.v1i1.23